-
Je něco špatně v tomto záznamu ?
EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis
G. Nagy, NMT. Roodenrijs, PMJ. Welsing, M. Kedves, A. Hamar, MC. van der Goes, A. Kent, M. Bakkers, P. Pchelnikova, E. Blaas, L. Senolt, Z. Szekanecz, EH. Choy, M. Dougados, JW. Jacobs, R. Geenen, JW. Bijlsma, A. Zink, D. Aletaha, L. Schoneveld,...
Jazyk angličtina Země Velká Británie
Typ dokumentu časopisecké články, směrnice pro lékařskou praxi, práce podpořená grantem
NLK
ProQuest Central
od 1939-01-01 do Před 6 měsíci
Health & Medicine (ProQuest)
od 1939-01-01 do Před 6 měsíci
Family Health Database (ProQuest)
od 1939-01-01 do Před 6 měsíci
- MeSH
- adherence k farmakoterapii MeSH
- antirevmatika aplikace a dávkování terapeutické užití MeSH
- cvičení MeSH
- hepatitida B komplikace farmakoterapie MeSH
- hepatitida C komplikace farmakoterapie MeSH
- kognitivně behaviorální terapie MeSH
- komorbidita MeSH
- lidé MeSH
- revmatoidní artritida komplikace diagnóza farmakoterapie terapie MeSH
- určení symptomu MeSH
- vzdělávání pacientů jako téma MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- směrnice pro lékařskou praxi MeSH
OBJECTIVE: To develop evidence-based European Alliance of Associations for Rheumatology (EULAR) points to consider (PtCs) for the management of difficult-to-treat rheumatoid arthritis (D2T RA). METHODS: An EULAR Task Force was established comprising 34 individuals: 26 rheumatologists, patient partners and rheumatology experienced health professionals. Two systematic literature reviews addressed clinical questions around diagnostic challenges, and pharmacological and non-pharmacological therapeutic strategies in D2T RA. PtCs were formulated based on the identified evidence and expert opinion. Strength of recommendations (SoR, scale A-D: A typically consistent level 1 studies and D level 5 evidence or inconsistent studies) and level of agreement (LoA, scale 0-10: 0 completely disagree and 10 completely agree) of the PtCs were determined by the Task Force members. RESULTS: Two overarching principles and 11 PtCs were defined concerning diagnostic confirmation of RA, evaluation of inflammatory disease activity, pharmacological and non-pharmacological interventions, treatment adherence, functional disability, pain, fatigue, goal setting and self-efficacy and the impact of comorbidities. The SoR varied from level C to level D. The mean LoA with the overarching principles and PtCs was generally high (8.4-9.6). CONCLUSIONS: These PtCs for D2T RA can serve as a clinical roadmap to support healthcare professionals and patients to deliver holistic management and more personalised pharmacological and non-pharmacological therapeutic strategies. High-quality evidence was scarce. A research agenda was created to guide future research.
Bács Kiskun County Hospital Rheumatology Department Kecskemét Hungary
Centre for Rheumatic Diseases King's College London London UK
Department of Genetics Cell and Immunobiology Semmelweis University Budapest Hungary
Department of Pharmacy Marin Hospital Asisstance Publique Hopitaux de Paris Hendaye France
Department of Psychology Utrecht University Utrecht The Netherlands
Department of Rheumatic Diseases Radboud University Nijmegen Medical Centre Nijmegen The Netherlands
Department of Rheumatology and Clinical Immunology Semmelweis University Budapest Hungary
Department of Rheumatology Bravis Hospital Roosendaal The Netherlands
Department of Rheumatology Faculty of Medicine University of Debrecen Debrecen Hungary
Department of Rheumatology Leiden University Medical Center Leiden The Netherlands
Department of Rheumatology Meander Medical Center Amersfoort The Netherlands
Epidemiology Unit German Rheumatism Research Centre Berlin Germany
EULAR Standing Committee of People with Arthritis Rheumatism in Europe Zurich Switzerland
Institute of Infection Immunity and Inflammation University of Glasgow Glasgow UK
Leeds Institute of Rheumatic and Musculoskeletal Medicine University of Leeds Leeds UK
Rheumatology Department King's College Hospital London UK
Salisbury Foundation Trust NHS Hospital Wiltshire UK
School of Health and Society Centre for Health Sciences Research University of Salford Salford UK
School of Medicine Catholic University of the Sacred Heart Rome Italy
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22011423
- 003
- CZ-PrNML
- 005
- 20220506125805.0
- 007
- ta
- 008
- 220425s2022 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1136/annrheumdis-2021-220973 $2 doi
- 035 __
- $a (PubMed)34407926
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Nagy, György $u Department of Rheumatology & Clinical Immunology, Semmelweis University, Budapest, Hungary nagy.gyorgy2@med.semmelweis-univ.hu $u Department of Genetics, Cell and Immunobiology, Semmelweis University, Budapest, Hungary $1 https://orcid.org/0000000311983228
- 245 10
- $a EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis / $c G. Nagy, NMT. Roodenrijs, PMJ. Welsing, M. Kedves, A. Hamar, MC. van der Goes, A. Kent, M. Bakkers, P. Pchelnikova, E. Blaas, L. Senolt, Z. Szekanecz, EH. Choy, M. Dougados, JW. Jacobs, R. Geenen, JW. Bijlsma, A. Zink, D. Aletaha, L. Schoneveld, P. van Riel, S. Dumas, Y. Prior, E. Nikiphorou, G. Ferraccioli, G. Schett, KL. Hyrich, U. Mueller-Ladner, MH. Buch, IB. McInnes, D. van der Heijde, JM. van Laar
- 520 9_
- $a OBJECTIVE: To develop evidence-based European Alliance of Associations for Rheumatology (EULAR) points to consider (PtCs) for the management of difficult-to-treat rheumatoid arthritis (D2T RA). METHODS: An EULAR Task Force was established comprising 34 individuals: 26 rheumatologists, patient partners and rheumatology experienced health professionals. Two systematic literature reviews addressed clinical questions around diagnostic challenges, and pharmacological and non-pharmacological therapeutic strategies in D2T RA. PtCs were formulated based on the identified evidence and expert opinion. Strength of recommendations (SoR, scale A-D: A typically consistent level 1 studies and D level 5 evidence or inconsistent studies) and level of agreement (LoA, scale 0-10: 0 completely disagree and 10 completely agree) of the PtCs were determined by the Task Force members. RESULTS: Two overarching principles and 11 PtCs were defined concerning diagnostic confirmation of RA, evaluation of inflammatory disease activity, pharmacological and non-pharmacological interventions, treatment adherence, functional disability, pain, fatigue, goal setting and self-efficacy and the impact of comorbidities. The SoR varied from level C to level D. The mean LoA with the overarching principles and PtCs was generally high (8.4-9.6). CONCLUSIONS: These PtCs for D2T RA can serve as a clinical roadmap to support healthcare professionals and patients to deliver holistic management and more personalised pharmacological and non-pharmacological therapeutic strategies. High-quality evidence was scarce. A research agenda was created to guide future research.
- 650 _2
- $a antirevmatika $x aplikace a dávkování $x terapeutické užití $7 D018501
- 650 _2
- $a revmatoidní artritida $x komplikace $x diagnóza $x farmakoterapie $x terapie $7 D001172
- 650 _2
- $a kognitivně behaviorální terapie $7 D015928
- 650 _2
- $a komorbidita $7 D015897
- 650 _2
- $a cvičení $7 D015444
- 650 _2
- $a hepatitida B $x komplikace $x farmakoterapie $7 D006509
- 650 _2
- $a hepatitida C $x komplikace $x farmakoterapie $7 D006526
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a adherence k farmakoterapii $7 D055118
- 650 _2
- $a vzdělávání pacientů jako téma $7 D010353
- 650 _2
- $a určení symptomu $7 D063189
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a směrnice pro lékařskou praxi $7 D017065
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Roodenrijs, Nadia M T $u Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands $1 https://orcid.org/0000000243643183
- 700 1_
- $a Welsing, Paco M J $u Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands
- 700 1_
- $a Kedves, Melinda $u Bács-Kiskun County Hospital, Rheumatology Department, Kecskemét, Hungary $1 https://orcid.org/0000000292715024
- 700 1_
- $a Hamar, Attila $u Department of Rheumatology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary $1 https://orcid.org/0000000233994801
- 700 1_
- $a van der Goes, Marlies C $u Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands $u Department of Rheumatology, Meander Medical Center, Amersfoort, The Netherlands
- 700 1_
- $a Kent, Alison $u Salisbury Foundation Trust NHS Hospital, Wiltshire, UK
- 700 1_
- $a Bakkers, Margot $u EULAR Standing Committee of People with Arthritis/Rheumatism in Europe (PARE), Zurich, Switzerland
- 700 1_
- $a Pchelnikova, Polina $u EULAR Standing Committee of People with Arthritis/Rheumatism in Europe (PARE), Zurich, Switzerland
- 700 1_
- $a Blaas, Etienne $u Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands
- 700 1_
- $a Senolt, Ladislav $u Department of Rheumatology, 1st Faculty of Medicine, Charles University and Institute of Rheumatology, Prague, Czech Republic
- 700 1_
- $a Szekanecz, Zoltan $u Department of Rheumatology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary $1 https://orcid.org/0000000277946844
- 700 1_
- $a Choy, Ernest H $u CREATE Centre, Section of Rheumatology, School of Medicine, Division of Infection and Immunity, Cardiff University, Cardiff, UK $1 https://orcid.org/0000000344598609
- 700 1_
- $a Dougados, Maxime $u Université de Paris Department of Rheumatology - Hôpital Cochin. Assistance Publique - Hôpitaux de Paris INSERM (U1153) Clinical epidemiology and biostatistics, PRES Sorbonne Paris-Cité, Paris, France
- 700 1_
- $a Jacobs, Johannes Wg $u Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands $1 https://orcid.org/0000000274383468
- 700 1_
- $a Geenen, Rinie $u Department of Psychology, Utrecht University, Utrecht, The Netherlands
- 700 1_
- $a Bijlsma, Johannes Wj $u Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands $1 https://orcid.org/0000000201288451
- 700 1_
- $a Zink, Angela $u Epidemiology Unit, German Rheumatism Research Centre, Berlin, Germany
- 700 1_
- $a Aletaha, Daniel $u Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria $1 https://orcid.org/0000000321080030
- 700 1_
- $a Schoneveld, Leonard $u Department of Rheumatology, Bravis Hospital, Roosendaal, The Netherlands
- 700 1_
- $a van Riel, Piet $u Department of Rheumatic Diseases, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
- 700 1_
- $a Dumas, Sophie $u Department of Pharmacy, Marin Hospital, Asisstance Publique-Hopitaux de Paris, Hendaye, France
- 700 1_
- $a Prior, Yeliz $u School of Health and Society, Centre for Health Sciences Research, University of Salford, Salford, UK $1 https://orcid.org/0000000198316254
- 700 1_
- $a Nikiphorou, Elena $u Centre for Rheumatic Diseases, King's College London, London, UK $u Rheumatology Department, King's College Hospital, London, UK $1 https://orcid.org/0000000168473726
- 700 1_
- $a Ferraccioli, Gianfranco $u School of Medicine, Catholic University of the Sacred Heart, Rome, Italy $1 https://orcid.org/0000000268844301
- 700 1_
- $a Schett, Georg $u Department of Internal Medicine 3, Rheumatology and Immunology, Friedrich-Alexander University of Erlangen-Nuremberg and Universitatsklinikum Erlangen, Erlangen, Germany $1 https://orcid.org/0000000187409615
- 700 1_
- $a Hyrich, Kimme L $u NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK $u Centre for Musculoskeletal Research, School of Biological Sciences, Faculty of Biology, Medicine & Health, University of Manchester, Manchester, UK $1 https://orcid.org/0000000182429262
- 700 1_
- $a Mueller-Ladner, Ulf $u Department of Rheumatology and Clinical Immunology, Justus-Liebig University Giessen, Campus Kerckhoff, Bad Nauheim, Germany
- 700 1_
- $a Buch, Maya H $u NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK $u Centre for Musculoskeletal Research, School of Biological Sciences, Faculty of Biology, Medicine & Health, University of Manchester, Manchester, UK $u Leeds Institute of Rheumatic & Musculoskeletal Medicine, University of Leeds, Leeds, UK $1 https://orcid.org/0000000208334852
- 700 1_
- $a McInnes, Iain B $u Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, UK
- 700 1_
- $a van der Heijde, Désirée $u Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands $1 https://orcid.org/000000025781158X
- 700 1_
- $a van Laar, Jacob M $u Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands $1 https://orcid.org/0000000155445785
- 773 0_
- $w MED00000444 $t Annals of the rheumatic diseases $x 1468-2060 $g Roč. 81, č. 1 (2022), s. 20-33
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/34407926 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20220425 $b ABA008
- 991 __
- $a 20220506125758 $b ABA008
- 999 __
- $a ok $b bmc $g 1789155 $s 1162621
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2022 $b 81 $c 1 $d 20-33 $e 20210818 $i 1468-2060 $m Annals of the rheumatic diseases $n Ann Rheum Dis $x MED00000444
- LZP __
- $a Pubmed-20220425
